Small Cap Feast
Small Cap Feast – 30 July 2020
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
Kibo Energy PLC, the multi-asset Africa focused energy company, is seeking admission for its 100% owned UK subsidiary Sloane Developments Ltd , which will be renamed Mast Energy Developments PLC (‘MED’), to the Standard List of the London Stock Exchange plc . Targeted for Q4 2020. The MED business strategy is to acquire and develop a portfolio of flexible small-scale power generation assets, exploiting a growth niche market in the UK for Reserve Power generation to balance out the national grid at critical times.
AEX Gold (TSXV:AEV) is intending to admit its shares to AIM alongside a £45m placing. The Company, led by CEO Eldur Ólafsson, has established the largest land package of gold assets in Greenland with a current portfolio of licences covering 3,356 square kilometres, in the two known gold belts in Southern Greenland, the Nanortalik and Tartoq gold belts. Nalunaq is a high-grade gold asset with an updated Inferred Mineral Resource covering 422,770 tonnes at 18.5 grams per tonne of gold, or 250,970 ounces of gold, which covers the area in and around the historical mine. Due 31 July. Current mkt cap C$66.7m.
Diurnal Group 52p £63.5m (DNL.L)
Trading Update: Alkindi® revenues for the year ended 30 June 2020 were £2.39m (year ended 30 June 2019: £1.04m), representing year-on-year growth of 130%. This strong performance was driven by new country launches and increased market penetration in the UK and Germany. Moreover, it was achieved despite challenges in access to hospital-based prescribing physicians due to Covid-19 restrictions, particularly in Italy where Alkindi® was launched in February 2020. Period end cash balance of £15.4m .
Today announces positive feedback from a pre-Investigational New Drug (IND) meeting with the US Food and Drug Administration (FDA) in relation to DITEST™ (native oral testosterone formulation), being developed by the Company as a treatment for male primary and secondary hypogonadism. The FDA has confirmed that DITEST™ can progress to a New Drug Application (NDA) via the 505 route.
Intercede 75p £37.8m (IGP.L)
The specialist in digital identity, credential management and secure mobility, announced its involvement in a successful bid for a ten-year contract with the U.S. Department of State (DoS) to create an innovative Identity Management System and Credential Management System (IDMS) solution compliant with Homeland Security Presidential Directive 12 (HSPD-12) for the DoS and its customers.
Yu Group 88.5p £14.4m (YU..L)
The independent supplier of gas, electricity and water to the UK corporate sector, today provides an update on trading for the six months ended 30 June 2020.
Group revenues for the period are expected to be approximately £45.0m (H1 2019: £56.6m), reflecting the impact of Covid-19 and the associated reduction in customer energy consumption. The Group is pleased to report that there has been a marked increase in customer demand throughout May and June and volumes are on trend to return to pre lockdown levels.
The Group’s swift response in implementing robust measures to reduce the risks associated with Covid-19 has ensured that the business has been able to continue to operate whilst supporting all customers. Despite the challenges faced, the Group has been able to achieve increased bookings growth during H1 2020. Average monthly sales bookings for H1 2020 were up significantly at £6.2m (H1 2019: £3.2m).
Volex 142.5p £217m (VLX.L)
AGM Statement from the global supplier of integrated manufacturing services and power products. “Unaudited revenue for the three months ended June 2020 was $96 million, which was flat on the same period a year earlier. Given the disruption caused by the global coronavirus pandemic, we are very pleased with this result. Operating profit remains at a similar level to the prior year, and our cash balance as at 24 July was $30 million. Our $30 million revolving credit facility remains available and undrawn.
As noted in our results statement on 18 June 2020, we continue to see weakness primarily in the medical installation sector, as hospitals around the world remain closed for non-critical medical procedures. In our electric vehicle business, demand is approaching pre-crisis levels as customers re-open their factories and consumer preference continues to shift towards electric vehicles. We continue to see resilient demand in our consumer electronics and data centre businesses.”
Oriole Resources 0.475p £4.33m (ORR.L)
The exploration company focused on West Africa, it has signed a US$250,000 sale agreement with its Joint Venture partner Bati Toroslar Madencilik Sanayi ve Ticaret Ltd. Ști in relation to its Hasançelebi and Doğala mining royalties in Turkey. The Sale Agreement will provide US$30,000 within seven days, with the balance contingent upon the commencement of mine construction at either Hasançelebi or Doğala. These royalties have no carrying value in the financial statements of the Company.
IronRidge Resources 15.5p £62m (IRR.L)
The African focussed minerals exploration company, reported multiple additional high-grade drilling results and the definition of significant targets from the ongoing second phase drilling programme at the Ehuasso target, as well as initial high-grade drilling results from reconnaissance drilling at the Ebilassokro target, both within the Zaranou Gold Project area (“Zaranou”). The license borders with Ghana and is along strike from significant operating gold mines including Chirano (5Moz), Bibiani (5.5Moz) and Ahafo (17Moz).
“Ongoing drilling at the Ehuasso target continues to define significant mineralised zones in the broad 160m spaced AC drill grid .
“The Ghana-Man pit is shaping up to be our most significant target defined to date over a potential strike length of 1.6km and up to 100m wide and including high-grade intersections such as, with additional target areas defined for future RC infill drilling.
“We are pleased to report promising reconnaissance drilling results including 20m at 1.09g/t gold in hole ZAAC0317 at the Ebilassokro target, situated 9km to the north-east of the Ehuasso target.
Fireangel Safety 12.5p £15.8m (FA..L)
The Company expects to report H1 2020 sales of approximately £16.5 million (H1 2019: £20.7 million) and an underlying operating loss of approximately £2.7 million (H1 2019: loss of £1.7 million). Within this result, the charge for non-cash depreciation and amortisation amounts to £1.9 million (H1 2019: £1.7 million). In light of the impact of COVID-19, the Board believes it has taken appropriate actions to protect the Company, its employees and customers. Given the extraordinary global events faced during the period, the Board considers the expected result for H1 2020 to be satisfactory and is encouraged by the strong start to the year made by the Company before domestic and international lockdown restrictions took hold.
Sales have been improving as a percentage of the Board’s pre-COVID-19 budget since May 2020 with performance in July 2020 expected to be in line with the revenue recorded in July 2019. Both Retail and Trade sales in the month are expected to be higher than in July 2019 illustrating a return to more normal patterns of customer demand behaviour which the Board anticipates will continue.
Blackbird 18p £60.5m (BIRD.L)
The developer and seller of the market-leading cloud video editing platform, Blackbird, has been chosen by Sky News Arabia for remote and collaborative cloud video editing and publishing of digital news content.
Sky News Arabia is a 24-hour Arabic news channel broadcast across the Middle East and North Africa (MENA). With a free-to-air TV channel, digital and audio platforms, Sky News Arabia delivers analysis of both news from the Middle East and North Africa region and international news. The channel is broadcast to more than 50 million households in the MENA region.
Omega Diagnostics 65p £116m (ODX.L)
the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the press release issued today by the UK Rapid Test Consortium (“UK-RTC”), of which Omega is a partner, on developing its COVID-19 lateral flow antibody test (the “AbC-19™ Rapid test”).
Further to the announcement on 29 June 2020 confirming design-freeze, Abingdon Health Limited, as lead partner of the UK-RTC, has today confirmed that it has CE-Marked the AbC-19™ Rapid test for professional use.
To achieve self-testing accreditation, pre-approval from the MHRA is required to perform self-test usability studies. The planned study will be performed by Ulster University using approximately 2,000 volunteers and, once complete, will allow the UK-RTC to seek final approval from the MHRA for self-test use. In addition, the test will also be subject to further independent evaluation.
Kazera Global 0.675p £4.6m (KZG.L)
Update on progress following its acquisition of Deep Blue Minerals on the 15th of last month:
- The Company has successfully negotiated the purchase of all necessary machinery and equipment for the commencement of operations.
- All of the machinery and equipment has now been delivered to the Company’s operational site in the Western Cape and has been made “mine ready”.
- All necessary staff have been recruited and have successfully undergone the required medical and security checks, as well as the mandated training.
- The above have all been achieved within budget and ahead of anticipated time scales.
- Deep Blue Minerals have secured a sub-contract to mine beach diamonds in addition to the existing sub-contract to mine land diamonds.
- Diamond mining will commence on 3 August 2020.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.